參考文獻 |
[1] Thomson, J. (1998). Embryonic Stem Cell Lines Derived from Human Blastocysts. Science, 282(5391), pp.1145-1147.
[2] Rippon, H. and Bishop, A. (2004). Embryonic stem cells. Cell Proliferation, 37(1), pp.23-34.
[3] Kehat, I., Kenyagin-Karsenti, D., Snir, M., Segev, H., Amit, M., Gepstein, A., Livne, E., Binah, O., Itskovitz-Eldor, J. and Gepstein, L. (2001). Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. Journal of Clinical Investigation, 108(3), pp.407-414.
[4] Watt, F. (2000). Out of Eden: Stem Cells and Their Niches. Science, 287(5457), pp.1427-1430.
[5] Annas et al. 1999; De Wert & Mummery 2003; Orive et al. 2003
[6] Vaiopoulos, A., Kostakis, I., Koutsilieris, M. and Papavassiliou, A. (2012). Colorectal Cancer Stem Cells. STEM CELLS, 30(3), pp.363-371.
[7] Clevers, H. (2011). The cancer stem cell: premises, promises and challenges. Nature Medicine, pp.313-319.
[8] Furth, J. & Kahn, M. The transmission of leukemia of mice with a single cell. Am. J. Cancer 31, 276–282(1937). (7的3)
[9] Kleinsmith, L.J. & Pierce, G.B. Jr. Multipotentiality of single embryonal carcinoma cells. Cancer Res. 24, 1544–1551(1964). (7的7)
[10] Plaks, V., Kong, N. and Werb, Z. (2018). The Cancer Stem Cell Niche: How Essential Is the Niche in Regulating Stemness of Tumor Cells?.
[11] Bonnet, D. and Dick, J. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3(7), pp.730-737.
[12] Al-Hajj, M., Wicha, M., Benito-Hernandez, A., Morrison, S. and Clarke, M. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences, 100(7), pp.3983-3988.
[13] Plaks, V., Kong, N. and Werb, Z. (2015). The Cancer Stem Cell Niche: How Essential Is the Niche in Regulating Stemness of Tumor Cells?. Cell Stem Cell, 16(3), pp.225-238.
[14] Vries RG, Huch M, Clevers H. Stem cells and cancer of the stomach and intestine. Mol Oncol 2010;4:373–384.
[15] Lobo NA, Shimono Y, Qian D et al. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007;23:675–699.
[16] Boman BM, Huang E. Human colon cancer stem cells: A new paradigm in gastrointestinal oncology. J Clin Oncol 2008;26:2828–2838.
[17] Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8: 755–768.
[18] Haegebarth A, Clevers H. Wnt signaling, Lgr5, and stem cells in the intestine and skin. Am J Pathol 2009;174:715–721.
[19] 19 Simons BD, Clevers H. Stem cell self-renewal in intestinal crypt. Exp Cell Res 2011;317:2719–2724.
[20] Tirino, V., Desiderio, V., Paino, F., De Rosa, A., Papaccio, F., La Noce, M., Laino, L., De Francesco, F. and Papaccio, G. (2013). Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. The FASEB Journal, 27(1), pp.13-24.
[21] Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010;120:41–50.
[22] Lugli A, Iezzi G, Hostettler I et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010;103: 382–390.
[23] Houghton J, Stoicov C, Nomura S et al. Gastric cancer originating from bone marrow-derived cells. Science 2004;306:1568–1571.
[24] Abdul Khalek FJ, Gallicano GI, Mishra L. Colon cancer stem cells. Gastrointest Cancer Res 2010(suppl 1):16–23.
[25] Fevr T, Robine S, Louvard D et al. Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. Mol Cell Biol 2007;27:7551–7559.
[26] Hardwick JC, Kodach LL, Offerhaus GJ et al. Bone morphogenetic protein signalling in colorectal cancer. Nat Rev Cancer 2008;8:806–812.
[27] Brittan M, Wright NA. Stem cell in gastrointestinal structure and neoplastic development. Gut 2004;53:899–910.
[28] Burness ML, Sipkins DA. The stem cell niche in health and malignancy. Semin Cancer Biol 2010;20:107–115.
[29] Vermeulen L, De Sousa EMF, van der Heijden M et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010;12:468–476.
[30] Monteiro J, Fodde R. Cancer stemness and metastasis: Therapeutic consequences and perspectives. Eur J Cancer 2010;46:1198–1203.
[31] Takaku K, Oshima M, Miyoshi H et al. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 1998;92:645–656.
[32] Bissell MJ, Labarge MA. Context, tissue plasticity, and cancer: Are tumor stem cells also regulated by the microenvironment? Cancer Cell 2005;7:17–23.
[33] Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011;331:1559–1564. 41 Sleeman JP, Nazarenko I, Thiele W. Do all roads lead to Rome? Routes to metastasis development. Int J Cancer 2011;128:2511–2526.
[34] Dittmar T, Heyder C, Gloria-Maercker E et al. Adhesion molecules and chemokines: The navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner. Clin Exp Metastasis 2008;25:11–32.
[35] Brooks SA, Lomax-Browne HJ, Carter TM et al. Molecular interactions in cancer cell metastasis. Acta Histochem 2010;112:3–25.
[36] Singh A, Settleman J. EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene 2010;29:4741–4751.
[37] Monteiro J, Fodde R. Cancer stemness and metastasis: Therapeutic consequences and perspectives. Eur J Cancer 2010;46:1198–1203.
[38] Takaku K, Oshima M, Miyoshi H et al. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 1998;92:645–656.
[39] Bissell MJ, Labarge MA. Context, tissue plasticity, and cancer: Are tumor stem cells also regulated by the microenvironment? Cancer Cell 2005;7:17–23.
[40] Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011;331:1559–1564.
[41] Sleeman JP, Nazarenko I, Thiele W. Do all roads lead to Rome? Routes to metastasis development. Int J Cancer 2011;128:2511–2526.
[42] Dittmar T, Heyder C, Gloria-Maercker E et al. Adhesion molecules and chemokines: The navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner. Clin Exp Metastasis 2008;25:11–32.
[43] 43 Brooks SA, Lomax-Browne HJ, Carter TM et al. Molecular interactions in cancer cell metastasis. Acta Histochem 2010;112:3–25.
[44] 44 Singh A, Settleman J. EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene 2010;29: 4741–4751.
[45] 45 Kong D, Li Y, Wang Z et al. Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: Are they cousins or twins? Cancers (Basel) 2011;3:716–729.
[46] 46 Dalerba P, Clarke MF. Cancer stem cells and tumor metastasis: First steps into uncharted territory. Cell Stem Cell 2007;1:241–242.47 Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: Mirage or reality? Nat Med 2009;15:1010–1012.
[47] Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science 2009;324:1670–1673.
[48] Hoshiba, T., Chen, G., Endo, C., Maruyama, H., Wakui, M., Nemoto, Tanaka, M. (2016). Decellularized Extracellular Matrix as anIn VitroModel to Study the Comprehensive Roles of the ECM in Stem Cell Differentiation. Stem Cells International, 2016, 1-10.
[49] Hoon DS, Ferris R, Tanaka R et al. Molecular mechanisms of metastasis. J Surg Oncol 2011;103:508–517.
[50] Sun YF, Yang XR, Zhou J et al. Circulating tumor cells: Advances in detection methods, biological issues, and clinical relevance. J Cancer Res Clin Oncol 2011;137:1151–1173.
[51] Iinuma H, Watanabe T, Mimori K et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes’ stage B and C colorectal cancer. J Clin Oncol 2011;29:1547–1555.
[52] Gazzaniga P, Gradilone A, Petracca A et al. Molecular markers in circulating tumour cells from metastatic colorectal cancer patients. J Cell Mol Med 2010;14:2073–2077.
[53] Salama P, Platell C. Colorectal cancer stem cells. ANZ J Surg 2009; 79:697–702.
[54] Rajasekhar VK, Dalerba P, Passegue E et al. The 5th International Society for Stem Cell Research (ISSCR) Annual Meeting, June 2007. Stem Cells 2008;26:292–298.
[55] Botchkina IL, Rowehl RA, Rivadeneira DE et al. Phenotypic subpopulations of metastatic colon cancer stem cells: Genomic analysis. Cancer Genomics Proteomics 2009;6:19–29.
[56] Cammareri P, Lombardo Y, Francipane MG et al. Isolation and culture of colon cancer stem cells. Methods Cell Biol 2008;86:311–324. 57 Dou J, Gu N. Emerging strategies for the identification and targeting of cancer stem cells. Tumour Biol 2010;31:243–253.
[57] Carvalho, J. L. (2012). Characterization of Decellularized Heart Matrices as Biomaterials for Regular and Whole Organ Tissue Engineering and Initial In-vitro Recellularization with Ips Cells. Journal of Tissue Science & Engineering,S11.
[58] Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445: 111–115.
[59] O’Brien CA, Pollett A, Gallinger S et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106–110.
[60] Horst D, Kriegl L, Engel J et al. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008;99:1285–1289.
[61] Horst D, Kriegl L, Engel J et al. CD133 and nuclear beta-catenin: The marker combination to detect high risk cases of low stage colorectal cancer. Eur J Cancer 2009;45:2034–2040.
[62] Kojima M, Ishii G, Atsumi N et al. Immunohistochemical detection of CD133 expression in colorectal cancer: A clinicopathological study. Cancer Sci 2008;99:1578–1583.
[63] Horst D, Scheel SK, Liebmann S et al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 2009;219:427–434.
[64] Artells R, Moreno I, Diaz T et al. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients. Eur J Cancer 2010;46:642–649.
[65] Huh JW, Park YS, Lee JH et al. CD133 mRNA expression and microsatellite instability in colorectal carcinoma. J Surg Oncol 2010;102:765–770.
[66] Wang Q, Chen ZG, Du CZ et al. Cancer stem cell marker CD133t tumour cells and clinical outcome in rectal cancer. Histopathology 2009;55:284–293.
[67] Elsaba TM, Martinez-Pomares L, Robins AR et al. The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer. PLoS One 2010;19:e10714.
[68] Kemper K, Sprick MR, de Bree M et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 2010;70:719–729.
[69] Osmond TL, Broadley KW, McConnell MJ. Glioblastoma cells negative for the anti-CD133 antibody AC133 express a truncated variant of the CD133 protein. Int J Mol Med 2010;5:883–888.
[70] Shmelkov SV, Butler JM, Hooper AT et al. CD133 expression is not restricted to stem cells, and both CD133t and CD133_ metastatic colon cancer cells initiate tumors. J Clin Invest 2008;118:2111–2120.
[71] Du L, Wang H, He L et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008;14:6751–6760.
[72] Huh JW, Kim HR, Kim YJ et al. Expression of standard CD44 in human colorectal carcinoma: Association with prognosis. Pathol Int 2009;59:241–246.
[73] Haraguchi N, Ohkuma M, Sakashita H et al. CD133tCD44t population efficiently enriches colon cancer initiating cells. Ann Surg Oncol 2008;15:2927–2933.
[74] Dalerba P, Dylla SJ, Park IK et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007;104:10158–10163.
[75] Chu P, Clanton DJ, Snipas TS et al. Characterization of a subpopulation of colon cancer cells with stem cell-like properties. Int J Cancer 2009;124:1312–1321.
[76] Todaro M, Perez Alea M, Scopelliti A et al. IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle 2008;7:309–313.
[77] Vermeulen L, Todaro M, de Sousa Mello F et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA 2008;105:13427–13432.
[78] Choi D, Lee HW, Hur KY et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 2009;15:2258–2264.
[79] Weichert W, Denkert C, Burkhardt M et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005;11:6574–6581.
[80] Yeung TM, Gandhi SC, Wilding JL et al. Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci USA 2010;107:3722–3727.
[81] Fan LF, Dong WG, Jiang CQ et al. Expression of putative stem cell genes Musashi-1 and beta1-integrin in human colorectal adenomas and adenocarcinomas. Int J Colorectal Dis 2010;25:17–23.
[82] Weichert W, Knosel T, Bellach J et al. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 2004;57:1160–1164
[83] Becker L, Huang Q, Mashimo H. Immunostaining of Lgr5, an intestinal stem cell marker, in normal and premalignant human gastrointestinal tissue. Scientific World Journal 2008;8:1168–1176.
[84] Barker N, Ridgway RA, van Es JH et al. Crypt stem cells as the cellsof- origin of intestinal cancer. Nature 2009;457:608–611.
[85] Kleist B, Xu L, Li G et al. Expression of the adult intestinal stem cell marker Lgr5 in the metastatic cascade of colorectal cancer. Int J Clin Exp Pathol 2011;4:327–335.
[86] Takahashi H, Ishii H, Nishida N et al. Significance of Lgr5(tve) cancer stem cells in the colon and rectum. Ann Surg Oncol 2011;18:1166–1174.
[87] Pang R, Law WL, Chu AC et al. A subpopulation of CD26t cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010;6:603–615.
[88] Chen Y, Orlicky DJ, Matsumoto A et al. Aldehyde dehydrogenase 1B1 (ALDH1B1) is a potential biomarker for human colon cancer. Biochem Biophys Res Commun 2011;405:173–179.
[89] Deng S, Yang X, Lassus H et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 2010;5:e10277.
[90] Carpentino JE, Hynes MJ, Appelman HD et al. Aldehyde dehydrogenase- expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res 2009;69:8208–8215.
[91] Saiki Y, Ishimaru S, Mimori K et al. Comprehensive analysis of the clinical significance of inducing pluripotent stemness-related gene expression in colorectal cancer cells. Ann Surg Oncol 2009;16: 2638–2644.
[92] Ong CW, Kim LG, Kong HH et al. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol 2010;23:450–457.
[93] Saigusa S, Tanaka K, Toiyama Y et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 2009;16:3488–3498.
[94] Navarro-Alvarez N, Kondo E, Kawamoto H et al. Isolation and propagation of a human CD133(_) colon tumor-derived cell line with tumorigenic and angiogenic properties. Cell Transplant 2010;19: 865–877.
[95] Massard C, Deutsch E, Soria JC. Tumour stem cell-targeted treatment: Elimination or differentiation. Ann Oncol 2006;17:1620–1624.
[96] Dylla SJ, Beviglia L, Park IK et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008;3:e2428.
[97] Schatton T, Frank NY, Frank MH. Identification and targeting of cancer stem cells. Bioessays 2009;31:1038–1049.
[98] Todaro M, Alea MP, Di Stefano AB et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin- 4. Cell Stem Cell 2007;4:389–402.
[99] Garibyan, L. & Fisher, D.E. How sunlight causes melanoma. Curr. Oncol. Rep. 12, 319-326, doi:10.1007/s11912-010-0119-y (2010).
[100] Eigentler, T.K., Meier, F., Keilholz, U., Hauschild, A., & Garbe, C. In: Der Onkologe, Vol. 16, Springer-Verlag, 1160-1166 (2010).
[101] 101 Hendijani, F. (2017). Explant culture: An advantageous method for isolation of mesenchymal stem cells from human tissues. Cell Proliferation, 50(2), p.e12334. |